A GBM, or glioblastoma, is the most aggressive and most common malignant brain tumor in adults. It carries a median survival of about 15 months with treatment, and fewer than 5% of patients survive five years after diagnosis. Glioblastoma is classified by the World Health Organization as a grade 4 tumor, the highest possible grade, meaning it grows rapidly and invades surrounding brain tissue.
Why GBM Is So Aggressive
Glioblastoma starts in glial cells, the supportive cells of the brain. What makes it particularly dangerous is the way it grows. Unlike many cancers that form a distinct mass, GBM cells spread diffusely into healthy brain tissue, weaving themselves into normal structures so thoroughly that surgeons cannot distinguish tumor from healthy brain, even under a surgical microscope.
The invading cells follow existing pathways in the brain. They travel along nerve fiber tracts, blood vessel walls, and the lining of the brain’s fluid-filled spaces, reaching sites far from the original tumor. As they move, they break down the structural scaffolding around them and disrupt the blood-brain barrier. This infiltrative behavior is a core reason why GBM almost always comes back after treatment. Even when the visible tumor is removed, individual cancer cells left behind in seemingly healthy tissue can seed new growth.
Common Symptoms
GBM symptoms depend on where the tumor sits in the brain, but several patterns are common. Headaches are often the first sign, particularly headaches that are worse in the morning, worsen when lying down, or become more frequent over days to weeks. Nausea and vomiting frequently accompany them.
Beyond headaches, people may notice:
- Cognitive changes: confusion, difficulty concentrating, memory problems, trouble making decisions
- Speech difficulties: trouble finding words, slurred speech, difficulty understanding language
- Vision changes: blurred or double vision, loss of peripheral vision
- Weakness: typically affecting one side of the body, including the face, arm, or leg
- Seizures: sometimes the very first symptom, even in someone with no seizure history
- Personality or mood shifts: irritability, emotional flatness, or uncharacteristic behavior
These symptoms develop because the growing tumor presses on brain tissue and increases pressure inside the skull. The specific combination of symptoms often gives doctors a clue about the tumor’s location before imaging confirms it.
How GBM Is Diagnosed
MRI is the primary imaging tool. On an MRI with contrast dye, glioblastoma has a characteristic look: a ring-shaped area of bright enhancement surrounding a darker center. That dark core is necrosis, or dead tissue, which is a hallmark of high-grade tumors. Surrounding the ring is usually a zone of swelling in the brain.
Imaging alone isn’t enough for a definitive diagnosis. A tissue sample, obtained either through a biopsy or during surgical removal, is needed to confirm the tumor type and grade. Pathologists also test the tissue for molecular markers that influence both prognosis and treatment decisions.
Molecular Markers That Matter
Two molecular features are especially important. The first is IDH status. Under the current WHO classification, a true glioblastoma is defined as “IDH-wildtype,” meaning the tumor lacks a specific mutation in the IDH gene. Brain tumors that look similar under the microscope but carry an IDH mutation are now classified differently and tend to have a better prognosis.
The second key marker is MGMT promoter methylation. MGMT is a protein that repairs the kind of DNA damage caused by chemotherapy. When the gene’s promoter region is “methylated” (essentially switched off), tumor cells produce less of this repair protein, making them more vulnerable to treatment. Patients whose tumors have MGMT methylation consistently live longer and respond better to chemotherapy. Those without it still receive the same treatment, though the benefit is more modest. Some research suggests that combining MGMT methylation status with actual protein levels gives the most accurate prediction of how a patient will respond.
Standard Treatment
Without any treatment, GBM has a median survival of roughly three months. The standard approach, established by a landmark clinical trial in 2005 and still the backbone of care today, involves three phases.
First, surgery aims to remove as much of the visible tumor as safely possible. Because GBM cells extend beyond the visible borders, complete removal is not achievable, but maximizing the amount taken out improves outcomes and relieves symptoms caused by pressure.
After recovery from surgery, patients begin about six weeks of daily radiation therapy combined with daily oral chemotherapy. This concurrent phase is followed by a four-week break, then six additional monthly cycles of chemotherapy alone, given for five days out of every 28-day cycle. This entire sequence, from surgery through the final chemotherapy cycle, spans roughly nine to ten months.
Tumor Treating Fields
A newer addition to the treatment toolkit is a wearable device that delivers low-intensity alternating electric fields to the scalp. These fields interfere with the ability of cancer cells to divide. In a major clinical trial for newly diagnosed GBM, adding this device to standard chemotherapy extended median overall survival from 16 months to about 20.6 months and nearly doubled the time before the tumor progressed (6.7 months versus 4 months).
The device requires wearing arrays of electrodes on a shaved scalp for at least 18 hours per day. It doesn’t cause the systemic side effects associated with chemotherapy, though skin irritation under the electrodes is common. For patients with recurrent GBM, the survival benefit has been less clear, but the treatment was associated with fewer severe side effects compared to additional chemotherapy.
When GBM Comes Back
Recurrence is nearly universal with glioblastoma. The infiltrative cells left behind after initial treatment eventually regrow, typically within months of completing therapy. There is no established standard of care for recurrent GBM, and treatment options are more limited the second time around.
Depending on the tumor’s location and the patient’s overall health, options may include a second surgery, a different chemotherapy regimen, or drugs that block the tumor’s blood supply. One such drug has been shown to extend survival by several months after recurrence, though outcomes remain poor. Clinical trials are often considered at this stage, as researchers are actively testing new approaches including immunotherapy and targeted therapies.
Factors That Influence Survival
While the overall statistics for GBM are sobering, individual outcomes vary. Several factors consistently predict longer survival: younger age at diagnosis, better overall health and functional status, the extent of surgical removal, and MGMT promoter methylation. Patients who have all of these favorable factors can sometimes survive well beyond the median, though long-term survival past five years remains rare at under 5%.
The 15-month median survival figure, while widely cited, reflects averages across all patients. For someone in good health with a tumor in an accessible location and favorable molecular markers, the expected trajectory may be meaningfully different from someone with the opposite profile. Understanding these individual factors is often more useful than focusing on the overall statistics alone.